Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase (Q37684920)

22 August 2017

1 reference

title

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase (English)

1 reference

22 August 2017

0 references

1 reference

Paul La Rosée

3

0 references

Andreas Hochhaus

object named as

Andreas Hochhaus

series ordinal

4

0 references

Hagop Kantarjian

series ordinal

1

object named as

Hagop M Kantarjian

1 reference

22 August 2017

2

Jorge Cortes

1 reference

PubMed ID

20120030

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

116

1 reference

22 August 2017

6

1 reference

22 August 2017

1419-1430

1 reference

Chronic myelogenous leukemia: biology and therapy

22 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

Inhibition of c-fms by imatinib: expanding the spectrum of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Bcr-Abl variants: biological and clinical aspects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Important therapeutic targets in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Characterization of Ph-negative abnormal clones emerging during imatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

An efficient rapid system for profiling the cellular activities of molecular libraries.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24928

7 January 2021

Identifiers

DOI

10.1002/CNCR.24928

1 reference

22 August 2017

1 reference

PubMed ID

20120030